Investors & Media
We are a vertically integrated, clinical stage gene therapy company with six ongoing clinical programs and a broad pipeline of preclinical and research programs. We have core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring and developing technologies that give us depth across both product candidates and indications. Our current focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia and xerophthalmia. Though initially focusing on the eye, salivary gland and central nervous system, we intend to expand our focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.
Data as of: 06/03/23 10:50 am EDT.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News ReleasesView All
May 16, 2023
MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual MeetingView News Release
May 11, 2023
MeiraGTx Reports First Quarter 2023 Financial and Operational ResultsView News Release
Associate Director, Real Chemistry